Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I, Fotakis G, Offermann A, Goveia J, Daum S, Salcher S, Noureen A, Timmer-Bosscha H, Schäfer G, Walenkamp A, Perner S, Beatovic A, Moisse M, Plattner C, Krogsdam A, Haybaeck J, Sopper S, Thaler S, Keller MA, Klocker H, Trajanoski Z, Wolf D, Pircher A.
Heidegger I, et al. Among authors: timmer bosscha h.
Mol Cancer. 2022 Jun 18;21(1):132. doi: 10.1186/s12943-022-01597-7.
Mol Cancer. 2022.
PMID: 35717322
Free PMC article.